End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
2.88 THB | +3.60% | -0.69% | -8.28% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company returns high margins, thereby supporting business profitability.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Sales forecast by analysts have been recently revised upwards.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- With a 2024 P/E ratio at 25.64 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- With an enterprise value anticipated at 3.52 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company appears highly valued given the size of its balance sheet.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-8.28% | 828M | B | ||
+18.92% | 81.04B | C+ | ||
-29.48% | 68.93B | B- | ||
+9.65% | 29.59B | C+ | ||
-0.14% | 17.24B | A- | ||
-9.30% | 16.99B | B | ||
+0.20% | 15.12B | A- | ||
+5.25% | 13.09B | B- | ||
+68.96% | 12B | C+ | ||
-2.88% | 11.94B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CHG Stock
- Ratings Chularat Hospital